University of California, San Francisco |
Guidelines for pre-exposure prophylaxis (PrEP)
The following guidelines from the CDC and other organizations provide comprehensive information on how to decide when and in whom to start PrEP; what to use; recommended baseline and follow-up laboratory and clinical monitoring; and special situations, including ambiguous HIV test results and considerations for PrEP use in specific populations.
PrEP Guidelines
Note: The guidelines on this page are updated in accordance with national updates. We keep all guidelines for archival purposes; please refer to the latest version.
2025 PrEP Guidelines:
- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis -United States, 2025
Open Link | From the Centers for Disease Control and Prevention (CDC)
2021 PrEP Guidelines:
- Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update
Open PDF | From the Centers for Disease Control and Prevention (CDC)
- Clinical Providers’ Supplement: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update
Open PDF | From the Centers for Disease Control and Prevention (CDC)
Other Guidances:
If you are interested in reading previous years’ CDC guidelines and recommendations pertaining to PrEP and the prevention of new HIV infections, please refer to their online archives. Other organizations such as IAS-USA and NYSDOH also maintain updated clinical recommendations on PrEP.